Corona-Nakamura Ana Luisa, Arias-Merino Martha Judith, Morfín-Otero Rayo, Rodriguez-Zavala Guillermo, León-Gil Alfredo, Camarillo-Escalera Juan Ramsés, Reyes-Cortés Idarmis Brisseida, Valdovinos-Ortega María Gisela, Nava-Escobar Erick René, Villaseñor-Corona Ana María de la Paz, Mireles-Ramírez Mario Alberto, Cisneros-Aréchiga Aldo Guadalupe, Torre Ofelia Padilla-De la, Pérez-Gómez Héctor Raúl, Rodríguez-Noriega Eduardo
High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico.
Western Clinical Research Institute, Zapopan 45030, Mexico.
J Clin Med. 2023 Jun 15;12(12):4065. doi: 10.3390/jcm12124065.
The aim of this study was to analyze the risk factors and predictors of mortality in a retrospective cohort of patients with coronavirus disease (COVID-19) who presented central nervous system (CNS) manifestations and complications when admitted to hospital. Patients hospitalized from 2020 to 2022 were selected. Demographic variables; history of neurological, cardiological and pulmonary manifestations; comorbidities; prognostic severity scales; and laboratory tests were included. Univariate and adjusted analyses were performed to determine risk factors and predictors of mortality. A forest plot diagram was used to show the strength of the associated risk factors. The cohort included 991 patients; at admission, 463 patients presented CNS damage and of these, 96 hospitalized patients presented de novo CNS manifestations and complications. We estimate a general mortality of 43.7% (433/991) and 77.1% (74/96), for hospitalized patients with de novo CNS manifestations and complications, respectively. The following were identified as risks for the development of hospital CNS manifestations and complications when in hospital: an age of ≥64 years, a history of neurological disease, de novo deep vein thrombosis, D-dimer ≥ 1000 ng/dL, a SOFA ≥ 5, and a CORADS 6. In a multivariable analysis, the mortality predictors were an age of ≥64 years, a SOFA ≥ 5, D-dimer ≥ 1000 ng/mL and hospital CNS manifestations and complications when admitted to hospital. Old age, being hospitalized in critical condition, and having CNS manifestations and complications in hospital are predictors of mortality in hospitalized patients with COVID-19.
本研究的目的是分析一组因新型冠状病毒肺炎(COVID-19)住院时出现中枢神经系统(CNS)表现和并发症的患者的回顾性队列中的死亡风险因素和预测指标。选取了2020年至2022年期间住院的患者。纳入了人口统计学变量;神经、心脏和肺部表现史;合并症;预后严重程度量表;以及实验室检查结果。进行单因素分析和校正分析以确定死亡的风险因素和预测指标。采用森林图展示相关风险因素的强度。该队列包括991例患者;入院时,463例患者存在CNS损害,其中96例住院患者出现新发CNS表现和并发症。我们估计,新发CNS表现和并发症的住院患者的总体死亡率分别为43.7%(433/991)和77.1%(74/96)。以下因素被确定为住院时发生医院CNS表现和并发症的风险因素:年龄≥64岁、神经疾病史、新发深静脉血栓形成、D-二聚体≥1000 ng/dL、序贯器官衰竭评估(SOFA)≥5分以及胸部CT报告和数据系统(CORADS)6级。在多变量分析中,死亡的预测指标为年龄≥64岁、SOFA≥5分、D-二聚体≥1000 ng/mL以及入院时的医院CNS表现和并发症。高龄、病情危重住院以及住院时出现CNS表现和并发症是COVID-19住院患者死亡的预测指标。